Microsoft Lands Landmark NHS Deal Even as Azure Cuts Jobs in China

NHS contract saves 43 minutes per person daily; Microsoft stock down 28% from high amid $190B capex and China layoffs. AI revenue run rate hits $37B.

The world’s largest generative AI deployment in healthcare is helping Microsoft prove its technology pays for itself, yet the company’s stock continues to trade in the doldrums. NHS England has signed a roughly £120 million contract to equip 505,000 clinical staff with Microsoft 365 Copilot — one of the biggest AI contracts ever awarded by the UK public sector.

The agreement follows a pilot spanning more than 30,000 NHS employees across 90 organisations that clocked an average time saving of 43 minutes per person per day — equivalent to five weeks of work annually. At full rollout, that could amount to 400,000 hours of freed-up capacity each month. The first 200,000 users are slated for onboarding within six months, with the remainder due by October.

Alongside standard licenses, NHS organisations will get access to Copilot Studio, allowing them to build custom agents that automate workflows ranging from HR queries to financial analysis. NHS England can develop agents centrally, while individual trusts can tailor solutions to their specific challenges. Microsoft is also advancing partnerships in health and biosciences with Mayo Clinic, First Foundation Labs, Causaly and Cortechs.ai.

Half a world away, the message is less optimistic. Microsoft is trimming its Azure workforce in Beijing and Shanghai, with reports indicating between 200 and 400 positions will be eliminated. Employees have been told their roles end on July 6. Some have been offered relocation to Canada. This marks the third round of job cuts in China in two years, driven by tightening data-transfer rules between Washington and Beijing. Other divisions — including the developer tools unit (DevDiv) and Microsoft’s AI team in Shanghai and Suzhou — are unaffected.

The contrasting moves come as the company’s financial engine runs at full throttle. In the third quarter of its 2026 fiscal year, Microsoft posted revenue of $82.89 billion — a year-on-year increase of 18.3%. Azure grew 40%, and the AI business crossed an annualised revenue run rate of $37 billion, up 123% from a year ago. The quarterly dividend of $0.91 per share, paid out today, offers little consolation to a stock that has shed nearly 28% from its 52-week high and trades at €344.95 in Europe. The relative strength index sits at 41.1, underscoring a technically bruised sentiment.

Part of the market’s caution stems from the sheer scale of capital spending. Microsoft plans around $190 billion in capex for 2026 — 61% higher than the prior year. CFO Amy Hood flagged an additional $25 billion in expected costs tied to rising component prices. Chief AI officer Mustafa Suleyman has also had to dial back earlier comments about job displacement from automation, stressing that AI takes over tasks rather than entire occupations.

The NHS contract offers something rare in the AI arena: independently verified productivity data and a committed multi-million-pound revenue stream. Whether that will shift the uneasy calculus between eye-watering capex and a flagging share price may become clearer once the full rollout is complete and the first efficiency reports land.